The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of The American Geriatrics Society

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 10404924
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Risk for Intracranial Hemorrhage after Tissue Plasminogen Activator Treatment for Acute Myocardial Infarction

  1998cited by this paper
• National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project.

  1998cited by this paper
• Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial.

  1998cited by this paper
• Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial

  1998cited by this paper
• A Survey of Management Practices for Isolated Systolic Hypertension

  1997cited by this paper
• Thrombolytic therapy for eligible elderly patients with acute myocardial infarction.

  1997cited by this paper
• Contemporary practice patterns in the management of newly diagnosed hypertension.

  1997cited by this paper
• Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.

  1997cited by this paper
• Evidence-based, cost-effective risk stratification and management after myocardial infarction. California Cardiology Working Group on Post-MI Management.

  1997cited by this paper
• The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment.

  1997cited by this paper
• Consumer/patient decision support in the new millennium: where should our research take us?

  1997cited by this paper
• Age-related trends (1986-1993) in the use of thrombolytic agents in patients with acute myocardial infarction. The Worcester Heart Attack Study.

  1997cited by this paper
• Antiarrhythmic Therapies for the Prevention of Sudden Cardiac Death

  1997cited by this paper
• Clarifying the Direct Relation between Total Cholesterol Levels and Death from Coronary Heart Disease in Older Persons

  1997cited by this paper
• When knowing enough is not enough.

  1997cited by this paper
• Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.

  1997cited by this paper
• Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• Patient health management: a promising paradigm in Canadian healthcare.

  1997cited by this paper
• A survey of clinician attitudes and management practices in hypertension

  1997cited by this paper
• The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review.

  1997cited by this paper
• Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

  1997cited by this paper
• Estimating Treatment Benefits for the Elderly: The Effect of Competing Risks

  1996cited by this paper
• Cardiovascular risk management among 1806 low risk patients in a primary care setting. Clinical Quality Improvement Network (CQIN) Investigators.

  1996cited by this paper
• Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly.

  1996cited by this paper
• Recent Age-Related Trends in the Use of Thrombolytic Therapy in Patients Who Have Had Acute Myocardial Infarction

  1996cited by this paper
• Aspirin for Secondary Prevention after Acute Myocardial Infarction in the Elderly: Prescribed Use and Outcomes

  1996cited by this paper
• The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study.

  1996cited by this paper
• Medical Therapy for Elderly Patients Who Have Had Myocardial Infarction: Too Little to the Late in Life?

  1996cited by this paper
• Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

  1996cited by this paper
• Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. European Secondary Prevention Study Group.

  1996cited by this paper
• Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

  1995cited by this paper
• Thrombolytic therapy for evolving myocardial infarction needs an approach that integrates benefit and risk.

  1995cited by this paper
• Can practice patterns and outcomes be successfully altered? Examples from cardiovascular medicine. The Clinical Quality Improvement Network (CQIN) Investigators.

  1995cited by this paper
• Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project.

  1995cited by this paper
• Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

  1995cited by this paper
• No magic bullets: a systematic review of 102 trials of interventions to improve professional practice.

  1995cited by this paper
• Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. The Clinical Quality Improvement Network (CQIN) Investigators.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Recent trends in hospital mortality of acute myocardial infarction--the Worcester Heart Attack Study. Have improvements been realized for all age groups?

  1994cited by this paper
• Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction.

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.

  1994cited by this paper
• Relationship of Age with Eligibility for Thrombolytic Therapy and Mortality Among Patients with Suspected Acute Myocardial Infarction

  1994cited by this paper
• By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

  1994cited by this paper
• Educational status and active life expectancy among older blacks and whites.

  1993cited by this paper
• Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.

  1993cited by this paper
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

  1993cited by this paper
• Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations.

  1993cited by this paper
• Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly.

  1992cited by this paper
• The exclusion of the elderly and women from clinical trials in acute myocardial infarction.

  1992cited by this paper
• Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.

  1992cited by this paper
• Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators.

  1991cited by this paper
• Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. The MITI Project Group.

  1991cited by this paper
• Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study.

  1990cited by this paper
• Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction.

  1988cited by this paper
• The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group.

  1988cited by this paper
• Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction.

  1988cited by this paper
• The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions.

  1985cited by this paper
• Benefit and cost analysis in geriatric care. Turning age discrimination into health policy.

  1984cited by this paper

• Disparities in Adoption of New Diabetic Therapies with Cardiovascular Benefits.

  2022cites this paper
• The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin

  2017cites this paper
• Assessing Knowledge Base on Geriatric Competencies for Emergency Medicine Residents

  2014cites this paper
• Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care?

  2011cites this paper
• Exploring the treatment-risk paradox in coronary disease.

  2007cites this paper
• A CD atterns and predictors of statin use after coronary artery ypass graft surgery

  2007cites this paper
• Patterns and predictors of statin use after coronary artery bypass graft surgery.

  2007cites this paper
• Impact of opinion leader-endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: a randomized controlled trial.

  2007cites this paper
• Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials.

  2007cites this paper
• Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG registry.

  2006cites this paper
• Acute myocardial infarction: quality of care in rural Alberta.

  2006cites this paper
• The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes.

  2004cites this paper
• Variabilidade entre cardiologistas na abordagem aos pacientes em prevenção secundária da cardiopatia isquêmica

  2004cites this paper
• Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies.

  2004cites this paper
• From knowledge to practice in chronic cardiovascular disease: a long and winding road.

  2004cites this paper
• Evidence based medicine and justice: a framework for looking at the impact of EBM upon vulnerable or disadvantaged groups

  2004cites this paper
• Variability among cardiologists in the management of patients under secondary prevention of ischemic heart disease.

  2004cites this paper
• International variation in the use of evidence-based medicines for acute coronary syndromes.

  2003cites this paper
• Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System.

  2003cites this paper
• Putting evidence into practice.

  2002cites this paper
• THE HUMAN AND ECONOMIC COSTS OF UNDERTREATMENT WITH STATINS

  2002cites this paper
• Are older people willing to give up their place in the queue for cardiac surgery to a younger person?

  2002cites this paper
• Paradoxical Relations of Drug Treatment with Mortality in Older Persons

  2001cites this paper
• Investigating the determinants of decreasing postmyocardial infarction mortality: an analysis of in-hospital data from 1992 and 1997.

  2001cites this paper
• Controlling the ischemic heart disease epidemic: strategies for the 21st century.

  2001cites this paper
• Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older

  2001cites this paper
• Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.

  2001cites this paper
• Equity in access to exercise tolerance testing, coronary angiography, and coronary artery bypass grafting by age, sex and clinical indications

  2001cites this paper
• Cost-effectiveness of statins

  2000cites this paper
• ATTITUDE OF CARDIOLOGISTS ON THE USE OF INVASIVE PROCEDURES IN FRAIL OLDER PATIENTS WITH CORONARY HEART DISEASE IN JAPAN

  2000cites this paper
• The care gap: improving delivery of patient care.

  2000cites this paper
• „Mangel des gesetzlichen Leistungssystems” - Möglichkeiten und Grenzen der medizinischen Sachverständigentätigkeit

  2000cites this paper
• Beta-blockers for congestive heart failure: what is the current consensus?

  2000cites this paper
• Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group.

  2000cites this paper
• ["Deficiencies in the mandatory health insurance system"--possibilities and limits of medical expert assessment].

  2000cites this paper
• Ageing and the cardiovascular system

  1999cites this paper